NJ Doctor Serge Menkin Loses DEA Registration Permanently
Published Date: 6/10/2025
Notice
Summary
Dr. Serge Menkin from New Jersey lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of January 31, 2025. This means Dr. Menkin can’t legally work with controlled drugs anymore, and the decision is final.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Menkin
The Drug Enforcement Administration revoked Serge Menkin, M.D.'s DEA Certificate of Registration No. BM8723795. The revocation is effective July 10, 2025, and follows findings that he is not authorized to handle controlled substances in New Jersey; his DEA registration had expired on January 31, 2025.
Pending and New New Jersey Registrations Denied
The Order denies any pending applications by Serge Menkin, M.D., to renew or modify his DEA registration and also denies any other pending application he has for additional registration in New Jersey. This denial is issued pursuant to the same Order effective July 10, 2025.
15-Day Reconsideration Right to Dispute Fact
The Order gives Serge Menkin, M.D., the right to file a properly supported motion for reconsideration of the Agency's factual finding that he lacks authority to handle controlled substances in New Jersey. Any such motion must be filed within fifteen calendar days of the date of the Order and served by email to the DEA Office of the Administrator at [email protected].
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-10501, Harry Kram, M.D.; Decision and Order
Dr. Harry Kram from California lost his DEA registration because he no longer has permission to handle controlled substances in his state. Despite being notified, he didn’t ask for a hearing, so the DEA officially revoked his registration by default. This means Dr. Kram can’t legally prescribe or handle controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
Next: 2025-10504, Takes of Marine Mammals Incidental to Specified Activities; Taking Marine Mammals Incidental to the Alaska Department of Transportation and Public Facilities Angoon Ferry Terminal Modification Project in Angoon, Alaska
The Alaska Department of Transportation is upgrading the Angoon Ferry Terminal in Alaska, and NOAA has given the green light for some marine mammals to be accidentally disturbed during the work. This permission lasts for one year and ensures the project won’t harm the animals or their homes. It’s a careful balance between improving transportation and protecting wildlife, all happening with clear rules and oversight.